Russell Patmore
Overview
Explore the profile of Russell Patmore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howell D, McCaughan D, Smith A, Patmore R, Roman E
PLoS One
. 2024 Aug;
19(8):e0293772.
PMID: 39163402
Background: Haematological malignancies (blood cancers) often follow chronic trajectories that can span many months or years. Management of these diseases typically involves periods of 'Watch & Wait', whereby patients are...
2.
Lamb M, Painter D, Howell D, Barrans S, Cargo C, de Tute R, et al.
Cancer Epidemiol
. 2023 Dec;
88:102513.
PMID: 38160571
Background: Population-based information on cancer incidence and outcome are required to inform clinical practice and research; but contemporary data are lacking for many lymphoid cancer subtypes. Methods: Set within a...
3.
Hewison A, Roman E, Smith A, McCaughan D, Sheridan R, Patmore R, et al.
Eur J Oncol Nurs
. 2023 Oct;
67:102421.
PMID: 37804754
Purpose: Improvements in chronic myeloid leukaemia treatment mean it is now relevant to examine the experiences of living with this cancer over a lifetime. This qualitative study aimed to investigate...
4.
Sheridan R, McCaughan D, Hewison A, Roman E, Smith A, Patmore R, et al.
BMJ Open
. 2023 Aug;
13(8):e070467.
PMID: 37597866
Objectives: Patients with chronic haematological cancers are often treated on a relapsing-remitting pathway, which may extend for many years. Such diagnoses are associated with uncertainties that often cause anxiety and...
5.
McCaughan D, Roman E, Sheridan R, Hewison A, Smith A, Patmore R, et al.
Eur J Oncol Nurs
. 2023 Jun;
65:102349.
PMID: 37331194
Purpose: Chronic blood cancers are incurable, and characterised by unpredictable, remitting-relapsing pathways. Management often involves periods of observation prior to treatment (if required), and post-treatment, in an approach known as...
6.
Phillips E, Burton C, Kirkwood A, Barrans S, Lawrie A, Rule S, et al.
EJHaem
. 2022 Jul;
1(1):133-141.
PMID: 35847742
Introduction: Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose-intense chemotherapy regimens, such as CODOX-M/IVAC. While rituximab has increased survival rates for most forms...
7.
Crouch S, Painter D, Barrans S, Roman E, Beer P, Cooke S, et al.
Blood Adv
. 2022 Apr;
6(21):5716-5731.
PMID: 35363872
Follicular lymphoma (FL) is morphologically and clinically diverse, with mutations in epigenetic regulators alongside t(14;18) identified as disease-initiating events. Identification of additional mutational entities confirms this cancer's heterogeneity, but whether...
8.
McCaughan D, Roman E, Smith A, Patmore R, Howell D
BMJ Open
. 2022 Mar;
12(3):e050816.
PMID: 35351694
Objectives: Haematological malignancies are the fifth most common cancer in the UK, with chronic subtypes comprising around a third of all new diagnoses. These complex diseases have some similarities with...
9.
Howell D, McCaughan D, Smith A, Patmore R, Roman E
PLoS One
. 2022 Feb;
17(2):e0263672.
PMID: 35143569
Objective: Most blood cancers are incurable and typically follow unpredictable remitting-relapsing pathways associated with varying need for treatment, which may be distressing for patients. Our objective was to conduct a...
10.
Roman E, Kane E, Howell D, Lamb M, Bagguley T, Crouch S, et al.
Int J Epidemiol
. 2022 Feb;
51(3):e87-e94.
PMID: 35134983
No abstract available.